Human Liver Cancer Associated Fibroblasts

Human Liver Cancer-Associated Fibroblasts (hCAFs) are primary stromal cells isolated directly from human hepatocellular carcinoma (HCC) specimens, representing the most abundant and functionally critical non-malignant constituents of the tumor microenvironment (TME). Unlike immortalized cell lines or animal xenografts, hCAFs preserve patient-specific genetic and epigenetic landscapes, sustain native activated myofibroblast phenotypes, and authentically recapitulate the intricate paracrine signaling networks that govern HCC progression, desmoplasia, and therapy resistance.

Predominantly derived from activated hepatic stellate cells, hCAFs constitutively express established CAF markers—including FAP-α, α-SMA, vimentin, and PDGFR-β—while secreting a potent array of tumor-modulating mediators such as TGF-β1, IL-6, HGF, and SDF-1/CXCL12. Through dynamic extracellular matrix remodeling and bidirectional crosstalk with neoplastic and immune compartments, they actively promote cancer cell proliferation, angiogenesis, epithelial-mesenchymal transition, and the establishment of an immunosuppressive niche, faithfully mirroring the pathophysiological complexity of the human HCC microenvironment in vivo. Contemporary single-cell transcriptomic and spatial omics analyses have further unveiled substantial inter-patient heterogeneity among hCAF subpopulations, highlighting their indispensable value in personalized biomarker discovery, patient stratification, and subtype-specific therapeutic targeting.

As a physiologically relevant ex vivo platform, hCAFs offer distinct and unparalleled experimental advantages: native secretory fidelity, superior translational predictability across diverse in vitro systems, and seamless compatibility with co-culture platforms, 3D organoid models, and high-throughput drug screening workflows. Moreover, their relative genetic stability compared to malignant cells renders them robust, druggable targets for mechanism-driven validation and stroma-directed therapeutic discovery. Collectively, these attributes position hCAFs as an essential and versatile resource for advancing precision oncology, accelerating drug development, and informing personalized HCC treatment strategies.